Bryan R. Haugen. MD is Professor of Medicine and Pathology at the University of Colorado School of Medicine and a member of the University of Colorado Cancer Center. He is also Chief of the Division of Endocrinology. Metabolism & Diabetes and Director of the Thyroid Tumor Program which provides care for more than 3.000 patients with thyroid cancer. He currently holds the Mary Rossick Kern and Jerome H. Kern Chair in Endocrine Neoplasms Research. Dr. Haugen received his BA degree in Chemistry from Saint Olaf College and medical degree from the Mayo Medical School in 1987. Internship. medical residency and endocrine fellowship were completed at the University of Colorado Health Sciences Center. Dr. Haugen is a Fellow in the American College of Physicians. and member of the Association of American Physicians (AAP). Dr Haugen was President of the American Thyroid Association (ATA) 2012-2013 and Chair of the ATA thyroid nodule and differentiated cancer guidelines task force which published the guidelines in Jan 2016. He has received the Paul Starr Award from the ATA for advancements in clinical thyroidology. His current clinical interests include thyroid neoplasms. advanced thyroid cancer. thyroid dysfunction and other endocrine tumors (parathyroid. adrenal. carcinoid). Dr. Haugens research interests include molecular studies of thyroid neoplasm diagnosis and pathophysiology as well as the study of molecular therapeutic targets. He is currently PI of 2 NCI R01 grants to study mechanisms and therapeutic targets in advanced thyroid cancer. Dr. Haugen led validation of a novel molecular test (called Afirma. marketed by Veracyte. Inc) that can help avoid unnecessary surgery in certain patients with thyroid nodules. His research group is also actively studying the individual host-tumor interaction in thyroid cancer to develop novel tumor immunology tests and therapies.
Dr Haugen has had a great interest in caring for patients with thyroid cancer and helping to find better treatments and management strategies for these patients for more than 20 years.